Eight Basel based startups will travel to Korea this summer to explore the market and seek internationalization opportunities. The nano-company Artidis joins the trip.
The Innovation Office of the University of Basel is supporting startups from Basel in their internationalization efforts from very early on. In particular, close relationships exist with Korea. “Korea is very advanced in innovation and its companies, hospitals & VC’s are open to work with Swiss healthcare startups. Our excellent and long-standing relationship with Korea provides the startups with the right access points and a supportive community to achieve success”, explains Christian Elias Schneider, Head of Innovation & Entrepreneurship at the University of Basel.
One of the eight participating startups is Artidis. The spin-off from the University of Basel developed first ever nano-mechnical biomarker for cancer by differentiating benign vs. malignant in less than 3 hours & defining treatment options based on the unique nano-mechanical signature of cancer cells. Artidis seeks to combine precise tissue measurement with data analytics to enable an individual and optimized treatment proposal.
In Korea, the startups will have meetings with a hospital to discuss clinical trial & validation collaboration and a Korean diagnostics company led by a Swiss-Korean CEO for market entry facilitation and business development. The trip also include the visit to the Seoul Biohub and its biotech & diagnostics startups as an incubation partner in Korea.